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Abstract 
Objective. A study is made of the efficacy and adverse effects of retinoid therapy applied to the white lesions of 
proliferative verrucous leukoplakia (PVL). Material and methods. The results of retinoid therapy were evaluated 
in 17 patients diagnosed with PVL. Topical retinoids were used in 5 patients, in the form of two daily applications 
of 0.1% 13-cis-retinoic acid in orabase for an average of 6.17+/-3.13 months. Systemic retinoids were used in 11 
patients, with the administration of 25 mg/day of acitretin in tablet form for an average of 5.41+/-2.02 months. 
One patient successively received the topical and systemic retinoid formulations. The course and results were 
evaluated on a blind basis by two investigators. The adverse effects of the medication were also assessed. Results. 
Clinical improvement was recorded for 7 lesions (38.8%) (six involving systemic treatment and one as a result 
of topical application). Clinical worsening was recorded in the same proportion (5 lesions with systemic therapy 
and two with topical treatment), while four lesions (22.4%) showed no changes (one lesion with systemic therapy 
and three with topical treatment). Adverse effects were documented in all the patients administered the systemic 
formulation, versus in only one patient administered topical retinoids. The most frequent problems were desqua-
mation and pruritus. Conclusion. Although topical or systemic retinoic acid produces some improvement in about 
one-third of all patients with PVL, further studies are needed to assess the efficacy and safety of these products, 
in view of the important percentage of individuals who worsen despite therapy, and the frequent appearance of 
adverse effects.
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Introduction
Proliferative verrucous leukoplakia (PVL) was first de-
scribed by Hansen et al. in 1985 (1). It is characterized 
by the appearance in the oral cavity of white plaques in 
multiple locations and with different forms of presen-
tation (homogeneous, patchy, verrucous) that progress 
towards oral squamous cell carcinoma in over 70% of 
all cases (2) – with the successive appearance of mul-
tiple primary tumors (a phenomenon known as “field 
cancerization”) (3). The etiology of the process remains 
unclear, and the treatments used (analogous to those 
usually employed in the management of leukoplakia) 
appear to be scantly effective in controlling the disease 
– though few studies on the treatment of PVL can be 
found in the literature. Femiano et al. (4) used meti-
soprinol (inosine) associated to surgery, with good re-
sults, and better than those obtained with surgery alone. 
Among the treatments used, mention can be made of the 
CO2 laser, surgery, surgery associated to radiotherapy, 
cryotherapy, topical vitamins, bleomycin and photody-
namic therapy with delta-aminolevulinic acid (ALA).
The present study was designed to assess the efficacy 
and adverse effects of systemic or topical retinoid ther-
apy applied to the white lesions of PVL.
Material and Methods
The study was carried out in the Service of Stomatology 
of Valencia University General Hospital, with approval 
from the Clinical Research Committee and Ethics Com-
mittee of the center.
Following usual clinical practice, use was made of 
retinoids (as 13-cis-retinoic acid 0.1% paste in orabase 
applied twice a day, or 25 mg acitretin tablets -Neotiga-
son®- once a day) in 17 patients diagnosed with PVL. 
Other potential study candidates were not included be-
cause they failed to follow regular therapy (5 patients), 
abandoned the treatment prematurely (6 patients), or 
because the photographic records failed to meet the 
requirements for adequate assessment of the lesions 
(2 patients). Of the 17 patients finally included in the 
study, 5 received treatment with 0.1% 13-cis retinoic 
acid paste, 11 received 25 mg acitretin tablets, and one 
successively received the topical and systemic retinoid 
formulations.
The necessary criteria for establishing the diagnosis of 
PVL were the following: simultaneous presence of sev-
eral leukoplasic lesions in the oral cavity; distribution 
of the white lesions in different zones of the oral cavity, 
with the progressive occupation of large mucosal exten-
sions; clinical follow-up of the lesions for at least two 
years or confirmation of progression to squamous cell 
carcinoma in cases with shorter follow-up, and histo-
logical confirmation of hyperkeratosis associated or not 
to variable degrees of epithelial dysplasia.
Women of child-bearing potential were not included in 
the study, due to the established teratogenicity of retin-
oids (category X of the United States FDA).
Photographic registries were obtained of all patients to 
assess the changes following treatment (i.e., response to 
the medication). We retrieved photographs of 18 white 
lesions in 17 patients diagnosed with PVL, obtained be-
fore and after treatment with retinoic acid. 
We thus obtained 18 pairs of images (before treatment-
after treatment) corresponding to the 17 included pa-
tients (two pairs of images were obtained in one patient). 
The images were subjected to evaluation on a blind basis 
by two investigators, with a view to identifying changes 
(improvement or worsening), or the absence of change 
as a result of treatment (Figures 1, 2 and 3). Investiga-
tors must evaluate changes in size and appearance of 
lesions, specifically changes from homogeneous to ver-
rucous or vice versa, and changes in colour. Changes in 
number of leukoplakias per patient were not evaluated. 
In cases of disagreement, the criterion of a third inves-
tigator was requested. If disagreement persisted among 
all three evaluators, the patient was removed from the 
study. The concordance between the two initial evalua-
tors was required to be ≥ 80%.
The patient clinical histories were likewise used to 
register the adverse effects occurring during treatment 
with any of the retinoid formulations. The evaluation of 
adverse effects was made among all patients who had 
received some dose of retinoids (topical or systemic) (25 
patients), independently of whether they were also in-
cluded in the image study group or not.
A descriptive statistical study was made (means and 
frequencies). Analytical statistics were not used, due to 
the presence of uncontrolled variables (severity or ini-
tial extent of the lesions, degree of dysplasia, previous 
carcinomas, etc.) that could have led to erroneous con-
clusions.
Results
The demographic and clinical dates of the patients are 
summarized in table 1.
The mean patient age was 61.44 years (range 43-85 
years, standard deviation –SD- ±12.49). Males were 
somewhat less numerous than females (41.2% versus 
58.8%). This proportion persisted on considering the to-
tal series of 30 patients in whom retinoic acid treatment 
in any of its forms had been indicated (56.6% females 
and 43.3% males). Mean time from the estimated be-
ginning of disease (PVL) to the start of treatment with 
retinoids was 77.5 months (SD±58.7 months).
As has been commented, PVL has a marked tendency 
to develop oral squamous cell carcinoma over time. In 
our study, 5 patients had developed at least one such 
carcinoma: three patients had developed one lesion, one 
patient developed two, and another had developed as 
many as 5 successive carcinomas in different localiza-
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Fig. 1. Improvement after treatment with retinoids. a: before treatment. b: after treatment.
Fig. 2. Without changes after treatment with retinoids. a: before treatment. b: after treatment.
Fig. 3. Worsening after treatment with retinoids. a: before treatment. b: after treatment.
a b
a
a
b
b
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n Age Sex Prev. treat. (a)
Prev. 
OSCC
(b)
Diag. to 
treat. (c)
Treat. 
(d)
Dur. 
treat. 
(e)
Objective im-
provement
(f)
Adverse effects
1 59 F 1 2 yes (2) 139 tabl. 6 no changes
Desquamation, erythema, it-
ching. Increased cholesterol and 
triglycerides
2 67 M 1 5 yes (1) 156 tabl. 9 worse
Hot flushes, photosensitivity. 
Increased cholesterol and tri-
glycerides
3 66 M 1 2 4 5 yes (5) 126 tabl. 8 improved Fragile nails, alopecia, desqua-mation, blurry vision
4 64 F 5 6 no 76 tabl. 5 worse Dry eyes and ocular itching
5 49 F 5 6 no 156 tabl. 4 improved Alopecia
6 74 F no yes (1) 26 pom. 8 worse No
7 85 F no yes (1) 60 tabl. 5 improved Pruritus
8 48 F 5 no 68 tabl. 5 worse Hyperglycemia, desquamation, pruritus, alopecia
9 70 F 3 5 no 56 tabl. 4 worse Dropout due to rectal bleeding and cramps
9* 70 F 3 5 no 60 pom. 6 worse No
10 73 M 5 no 24 tabl. 8 improved Alopecia
11 56 M 5 1 no 124 tabl. 2 improved Desquamation, bleeding, itching
12 45 M 5 1 no 24 tabl. 5 worse Very intense desquamation, pruritus
13 47 F 5 no 144 pom. 4 no changes No
14 75 F 5 no 35 pom. 11 improved Itching
15 52 M no no 17 pom. 2 no changes No
16 69 F no no 24 pom. 6 no changes No
17 43 M 4 no 124 tabl. 4 improved
Desquamation, pruritus. In-
creased cholesterol and trigly-
cerides
Table 1. Data of the patients included in the evaluation of photographic registries.
(a) Previous treatment: 1 topical corticoids. 2 systemic corticoids. 3 topical immunosuppressors. 4 retinoic acid. 5 laser vaporization. 6. con-
ventional surgery; (b) Previous oral squamous cell carcinomas (number shown in parenthesis); (c) Time in months from diagnosis of the disease 
to start of treatment with retinoids; (d) Type of treatment with retinoids: pom=paste, tabl=tablets; (e) Duration in months of treatment with 
retinoids; (f) Evolution of the lesions according to the evaluators. *The rows headed by the number 9 correspond to the same patient. OSCC = 
oral squamous cell carcinoma.
Frequent No. of patients Isolated No. of patients
Pruritus (itching) 9 Asthmatic crisis 1
Desquamation 8 Rectal bleeding 1
Alopecia 5 Hyperglycemia 1
Dyslipidemia 4 Joint pain 1
Fragile nails 4 Cramps 1
Hot flushes / reddening 3 Dry mouth 1
Blurry vision 3 Photosensitivity 1
Table 2. Adverse effects seen in the 25 patients treated with retinoids.
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tions of the oral cavity. All these carcinomas had devel-
oped previously to the introduction of treatments with 
retinoids. Two patients developed oral squamous cell 
carcinomas during the period in which they were re-
ceiving retinoic acid or in the period immediately after 
the end of treatment (3 months). These two patients had 
received systemic retinoids. The tumors were located in 
the cheek mucosa and left lateral margin of the tongue, 
respectively, and both were successive primary lesions: 
in one of the patients the tumor represented the second 
carcinoma, while in the other it corresponded to the 
third recorded lesion. 
The mean duration of retinoid treatment was 5.41 ± 2.02 
months in the case of the systemic retinoids, and 6.17 ± 
3.13 months for the topical retinoids. Globally, the mean 
duration of treatment was 5.67 ± 2.37 months (range 
2-11 months). The mean time from initial diagnosis of 
the disease to the start of retinoid treatment was about 
6.5 years (80.11 months, range 24-156, SD ±51.06).
Concordance between the initial evaluators was 94%. 
Only in one case the third evaluator was required. So, 
no patients were excluded from the study because of 
disagreement between evaluators. These investigators 
detected clinical improvement in 38.8% of the evaluated 
lesions. Worsening was documented in the same pro-
portion of lesions, while four lesions (22.4%) showed no 
changes after treatment. Of the 7 lesions that were seen 
to have improved, 6 had been treated with tablets and 
one with paste. As regards the lesions that worsened, 5 
had been treated with tablets and two with paste. One 
of the lesions in which no changes were noted had been 
treated with tablets, and the other three with paste.
The most frequent adverse effects were skin desqua-
mation and pruritus. Alopecia was also common, as 
were slight elevations in serum cholesterol and triglyc-
erides, fragile nails, hot flushes and blurry vision. All 
the patients administered systemic retinoid treatment 
suffered some type of adverse effect, and four of them 
had to suspend the treatment as a result: two because 
of intense pruritus, one due to asthma crisis, and one 
because of rectal bleeding. In all four patients the symp-
toms disappeared after suspending the medication. The 
recorded adverse effects are shown in Table 2.
Discussion
Proliferative verrucous leukoplakia (PVL) manifests in 
the form of white lesions distributed over one or more 
locations within the oral cavity, and which are clinically 
and histologically indistinguishable from typical leuko-
plakia lesions. The disease can remain without change 
for years; it is therefore understandable that the treat-
ments used for the white lesions of PVL are the same 
as those applied to leukoplakias. On the other hand, as 
a result of the refractory nature of the lesions, a broad 
range of therapeutic approaches known to have some ef-
fect in patients with leukoplakia have also been used to 
treat PVL. However, very few publications in the litera-
ture have specifically addressed the treatment of PVL.
The published series of patients diagnosed with PVL in-
clude smokers. Hansen, in the study that described the 
disease for the first time (1), reported that 62% of the pa-
tients consumed tobacco in one form or other. Zakrews-
ka et al. (5) in turn reported a 70% of smokers (7 of 10), 
while Silverman et al. (6) reported 31%. Bagán et al. (7) 
reported the lowest presence of smokers (23.3%). In our 
study, two of the 17 patients (11.8%) were smokers (both 
were women), while four were ex-smokers (23.6%) with 
a mean smoking cessation period of 9.75 years. All the 
patients in the study except two had received previous 
treatments for their oral lesions (laser, surgery or corti-
coids). In all of them the lesions failed to disappear or 
did not change despite treatment, or the lesions relapsed 
shortly after the end of treatment. This coincides with 
the observations of Hansen (1) who reported relapses 
despite treatment in 28 of 29 patients (radiotherapy, 
surgery, chemotherapy, multiple resections, laser, retin-
oids, other therapies). Silverman et al. (6), using surgery 
and surgery associated to radiotherapy, reported a per-
centage persistence of disease (live subjects with PVL 
or patients who died as a consequence of oral squamous 
cell carcinoma) of 85% after a mean follow-up of 11.6 
years. These authors thus reported a 15% disease-free 
rate. Our series showed a greater female prevalence of 
PVL (56.6% females and 43.3% males) – in coincidence 
with the observations of Hansen, Bagán Silverman and 
Cabey. 
The primary objective of leukoplakia therapy should 
be the prevention of malignant transformation. Retin-
oids – which possess inhibitory action upon epithelial 
tissue proliferation and keratinization (8) – have been 
used in topical or systemic form for the treatment of leu-
koplakias. In our series we used 13-cis-retinoic acid for 
topical treatment and acitretin for sistemic treatment. 
Other retinoids as fenretinide were not considered in 
our study because it is not marketed nowadays in Spain. 
Hong et al. (9) employed 13-cis-retinoic acid in 24 pa-
tients with leukoplakia at a dose of 1-2 mg/kg/day dur-
ing three months. They recorded improvement (lesion 
size reduction) in 16 patients (67%) though there were 
relapses 2-3 months after treatment. In our series, 6 of 
the subjects treated improved of the disease, though 5 
worsened despite of treatment, probably in relation to 
the progressive character of PVL. Silverman et al. (10) 
obtained complete resolution of the lesions in 44% of 
their patients using systemic vitamin A, while Sankara-
narayanan et al. (11) reported the complete regression of 
precancerous lesions with systemic vitamin A in 52% of 
their patients. Although the improvement rates found by 
the authors are similar to our own (in the order of 50% 
among the patients administered systemic retinoids), we 
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consider it significant that none of the mentioned stud-
ies reported worsening of the lesions in spite of (or be-
cause of) the treatment provided. Our hypothesis is that 
worsening reflects the natural course (i.e., progression) 
of PVL rather than worsening because of treatment.
The results obtained on using topical retinoids for the 
treatment of leukoplakias, involving variable concen-
trations of tretinoin or isotretinoin in gel form (0.05% 
to 0.1%), are generally similar to those obtained with 
systemic retinoids. Shah (12) and Epstein et al. (13) ob-
tained complete response in about 27% of their patients, 
with a partial response in 54%. Boisnic et al. (14), using 
0.1% retinaldehyde gel, observed the resolution of 17% 
of their leukoplakias, with improvement in 75%. The 
use of higher concentrations of topical isotretinoin in-
duced a significant reduction of the leukoplakia lesions 
without causing local or systemic adverse reactions (15). 
Of note is the fact that authors such as Piattelli et al. (16) 
obtained some degree of favorable response in 100% of 
their patients treated with 0.1% isotretinoin. The results 
recorded in relation to topical treatment clearly dif-
fer from our own, since we observed improvement in 
only one patient, with worsening in two subjects, and 
no changes in another three patients. These differences 
again could be explained by the different evolutive pat-
tern of leukoplakias compared with PVL.
Overall, when considering the use of retinoids for the 
treatment of PVL, the most significant findings are per-
haps the absence of clinical resolution of the white le-
sions in any of our patients (in contrast to the findings 
of other authors in patients with leukoplakias unrelated 
to PVL), and the worsening seen in a percentage of our 
patients despite the treatment provided (this not being 
observed or at least not reported by other authors who 
have used retinoids to treat leukoplakia).
The mean time of leukoplakia evolution towards oral 
squamous cell carcinoma varies in the literature from 
4.4 years according to Bagán et al. (3) to 11.6 years as 
documented by Silverman and Gorsky (6). The time 
from first carcinoma to successive carcinomas in PVL 
patients has only been documented by Bagán et al., who 
recorded a mean time from first to second oral squamous 
cell carcinoma of 19.20 ±13.41 months, and a mean time 
from second to third carcinoma of 17.47±6.63 months. 
Lodi et al (17) in a systematic review about treatment of 
leukoplakias concluded that none of the therapies evalu-
ated (including retinoids) offered benefit versus placebo 
in preventing the malignant transformation of leuko-
plakia. In our study, the appearance of two carcinomas, 
one of them during the period of treatment and the other 
in the immediate posterior period, supports the hypoth-
esis that retinoids do not modify the natural evolution of 
PVL to oral squamous cell carcinomas. 
A particularly relevant aspect of treatment with retin-
oids is its important toxicity, especially when admin-
istered via the systemic route. All our patients who 
received systemic retinoids suffered adverse effects as-
sociated to treatment, while in contrast only one patient 
in the topical treatment group experienced problems in 
the form of itching in the oral cavity. The most frequent 
adverse effects cheilitis, desquamation, pruritus, alope-
cia and rhinitis. Most of the adverse effects recorded 
in our series coincided with the known side effects of 
retinoids (pruritus, skin desquamation, alopecia, fragile 
nails, triglyceride alterations, etc). However, two of the 
patients suffered serious adverse effects not described 
in the Summary of Product Characteristics of the medi-
cation used. In effect, after three months of treatment, 
one of the patients administered 25 mg of acitretin/day 
developed intense rectal bleeding and cramps of the 
extremities that made standing and walking difficult. 
Suppression of the drug led to resolution of these mani-
festations. Another patient with the same treatment de-
veloped an asthmatic crisis related to acitretin. 
In conclusion, although topical or systemic retinoic 
acid offers some degree of improvement in a little over 
one-third of all patients with PVL, the large proportion 
of individuals who worsen despite treatment, and the 
high frequency of adverse effects, make it necessary to 
conduct experimental studies before indicating or con-
traindicating the use of retinoids for the treatment of 
proliferative verrucous leukoplakia.
References
1. Hansen LS, Olson JA, Silverman S Jr. Proliferative verrucous leu-
koplakia. A long-term study of thirty patients. Oral Surg Oral Med 
Oral Pathol. 1985;60:285-98. 
2. Cabay RJ, Morton TH Jr, Epstein JB. Proliferative verrucous leu-
koplakia and its progression to oral carcinoma: a review of the litera-
ture. J Oral Pathol Med. 2007;36:255-61. 
3. Bagán JV, Murillo J, Poveda R, Gavaldá C, Jiménez Y, Scully 
C. Proliferative verrucous leukoplakia: unusual locations of oral 
squamous cell carcinomas, and field cancerization as shown by the 
appearance of multiple OSCCs. Oral Oncol. 2004;40:440-3. 
4. Femiano F, Gombos F, Scully C. Oral proliferative verrucous 
leukoplakia (PVL); open trial of surgery compared with combined 
therapy using surgery and methisoprinol in papillomavirus-related 
PVL. Int J Oral Maxillofac Surg. 2001;30:318-22. 
5. Zakrzewska JM, Lopes V, Speight P, Hopper C. Proliferative ver-
rucous leukoplakia: a report of ten cases. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod. 1996;82:396-401. 
6. Silverman S Jr, Gorsky M. Proliferative verrucous leukoplakia: 
a follow-up study of 54 cases. Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod. 1997;84:154-7. 
7. Bagan JV, Jimenez Y, Sanchis JM, Poveda R, Milian MA, Murillo 
J, et al.  Proliferative verrucous leukoplakia: high incidence of gingi-
val squamous cell carcinoma. J Oral Pathol Med. 2003;32:379-82. 
8. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Cur-
rent use and future potential role of retinoids in dermatology. Drugs. 
1997;53:358-88. 
9. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et 
al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J 
Med. 1986;315:1501-5. 
10. Silverman S Jr, Renstrup G, Pindborg JJ. Studies In Oral Leuko-
plakias. VII. Further Investigations On The Effects Of Vitamin A On 
Keratinization. Acta Odontol Scand. 1963;21:553-70. 
e9
Med Oral Patol Oral Cir Bucal. 2010 Jan 1;15 (1):e3-9.                                                                                                                                        Retinoids and proliferative verrucous leukoplakia
11. Sankaranarayanan R, Mathew B, Varghese C, Sudhakaran PR, 
Menon V, Jayadeep A, et al. Chemoprevention of oral leukopla-
kia with vitamin A and beta carotene: an assessment. Oral Oncol. 
1997;33:231-6. 
12. Shah JP, Strong EW, DeCosse JJ, Itri L, Sellers P. Effect of retin-
oids on oral leukoplakia. Am J Surg. 1983;146:466-70. 
13. Epstein JB, Gorsky M. Topical application of vitamin A to oral 
leukoplakia: A clinical case series. Cancer. 1999;86:921-7. 
14. Boisnic S, Licu D, Ben Slama L, Branchet-Gumila MC, Szpirglas 
H, Dupuy P. Topical retinaldehyde treatment in oral lichen planus 
and leukoplakia. Int J Tissue React. 2002;24:123-30. 
15. Scardina GA, Carini F, Maresi E, Valenza V, Messina P. Evalua-
tion of the clinical and histological effectiveness of isotretinoin in the 
therapy of oral leukoplakia: ten years of experience: is management 
still up to date and effective? Methods Find Exp Clin Pharmacol. 
2006;28:115-9. 
16. Piattelli A, Fioroni M, Santinelli A, Rubini C. Bcl-2 expression 
and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically 
treated oral leukoplakia: a pilot study. Oral Oncol. 1999;35:314-20. 
17. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interven-
tions for treating oral leukoplakia. Cochrane Database Syst Rev. 
2006;4:CD001829. 
 
